Logo image of BSTC

Biospecifics Tech Cp (BSTC) Stock News

NASDAQ:BSTC - Nasdaq -

88.53  +0.13 (+0.15%)

After market: 88.45 -0.08 (-0.09%)

BSTC Latest News, Press Relases and Analysis

News Image
5 years ago - BioSpecifics Technologies Corp.

BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals

Mentions: ENDP

News Image
5 years ago - Halper Sadeh LLP

SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – BSTC, UROV, CXO

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ:BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Endo International plc for $88.50 per share. If you are a BioSpecifics shareholder, click on this link to learn more about your rights and

Mentions: UROV CXO

News Image
5 years ago - Zacks Investment Research

BioSpecifics Technologies (BSTC) Surpasses Q3 Earnings and Revenue Estimates

BioSpecifics (BSTC) delivered earnings and revenue surprises of 315.79% and 106.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

News Image
5 years ago - BioSpecifics Technologies Corp.

BioSpecifics Reports Third Quarter 2020 Financial and Operating Results

- Endo acquisition of BioSpecifics expected to close in 4Q20

News Image
5 years ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – BSTC, CBLI, PE, GLIBA

NEW YORK, NY / ACCESSWIRE / November 7, 2020 /Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ:BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Endo International plc for $88.50 per share. If you are a BioSpecifics shareholder, click on this link to learn more about your rights and

Mentions: PE CBLI

News Image
5 years ago - Zacks Investment Research

Earnings Preview: BioSpecifics Technologies (BSTC) Q3 Earnings Expected to Decline

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News Image
5 years ago - Zacks Investment Research

Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised

Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.

Mentions: ENDP RDY NVAX

News Image
5 years ago - WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.

URGENT - TENDER OFFER EXPIRES DECEMBER 1, 2020

News Image
5 years ago - Halper Sadeh LLP

ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations - GLIBA, CXO, RESI, BSTC

NEW YORK, NY / ACCESSWIRE / October 27, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: GCI Liberty, Inc. (NASDAQ:GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Liberty Broadband Corporation. Visit our website to learn more about your legal rights and options:

Mentions: CXO RESI

News Image
5 years ago - Zacks Investment Research

Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

Mentions: BIIB REGN GILD VRTX ...

News Image
5 years ago - Benzinga

The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (...

Mentions: OCX ALEC BIIB XTLB ...

News Image
5 years ago - Zacks Investment Research

Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M

Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.

Mentions: ENDP VRTX NVAX